drugset / Trial / NCT00324454

Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease

NCT00324454

Phase 2 Completed 20 enrolled Duke University UCB Pharma · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effective therapy exists: cramps, spasticity, and disease progression.

Timeline

Start
2006-05
Primary completion
2007-12
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1500 mg